二、报告期经销商变动情况 | 地区 | | 2023 年第二季度 | | | | --- | --- | --- | --- | --- | | | 期初 增加 | | 减少 | 期末 | | 东北 | 41 | 26 | 18 | 49 | | 华北 | 110 | 43 | 56 | 97 | | 华东 | 456 | 130 | 241 | 345 | | 华南 | 61 | 13 | 24 | 50 | | 华中 | 87 | 27 | 38 | 76 | | 西北 | 18 | 7 | 11 | 14 | | 西南 | 48 | 7 | 26 | 29 | | 总计 | 821 | 253 | 414 | 660 | 三、报告期内无其他对公司生产经营具有重大影响的事项。 证券代码：603739 证券简称：蔚蓝生物 公告编号：2023-058 青岛蔚蓝生物股份有限公司 2023 年度第二季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 青岛蔚蓝生物股份有限公司（以下简称"公司"）根据上海证券交易所《 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2023-055 表决结果：5 票赞成，0 票反对，0 票弃权。 2、审议通过《关于<公司 2023 年半年度募集资金存放与实际使用情况的专 项报告>的议案》 具体内容详见公司在上海证券交易所网站(www.sse.com.cn)披露的《青岛蔚 蓝生物股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告》 （公告编号：2023-057）。 青岛蔚蓝生物股份有限公司 关于公司第五届董事会第三次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 青岛蔚蓝生物股份有限公司（以下简称"公司"）第五届董事会第三次会议 于 2023 年 8 月 24 日在公司会议室以通讯和现场表决的方式召开，会议通知已于 2023 年 8 月 14 日以邮件形式发出。本次会议应出席董事 5 人，实际出席 5 人。 会议由公司董事长陈刚先生主持。会议召集召开程序及审议事项符合《中华人民 共和国公司法》和《青岛蔚蓝生物股份有限公司章程》等有关规定，所形成的 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2023-057 青岛蔚蓝生物股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》及相关格式指引的规定，青岛蔚蓝生物股份有限公 司（以下简称"公司"）现将 2023 年半年度募集资金存放与实际使用情况专项说 明如下： 一、募集资金基本情况 （一）首次公开发行募集资金 1、实际募集资金金额及资金到账时间 经中国证券监督管理委员会证监许可[2018]1961 号文核准，公司向社会公 众公开发行人民币普通股(A 股)股票 3,866.70 万股，发行价为每股人民币 10.19 元，共计募集资金 394,016,730.00 元，扣除各项发行费用后，实际募集资金净 额为人民币 347,440,291.00 元。上述募集资金已于 2019 年 1 月 9 日到位，已经 瑞华会计师事务所（特殊普通合伙）验证，并由其出具《验资 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2023-054 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次交易概述 青岛蔚蓝生物股份有限公司（以下简称"公司"）于 2023 年 7 月 20 日召开 了第五届董事会第二次会议，以"5 票赞成、0 票反对、0 票弃权"的表决结果 审议通过了《关于收购青岛润博特生物科技有限公司 51%股权的议案》，同意公 司以自有资金 9,180 万元收购秦伟、秦启龙、张小东、陈强、青岛聚润管理咨询 合伙企业（有限合伙）和青岛格润普管理咨询合伙企业（有限合伙）合计持有的 青岛润博特生物科技有限公司（以下简称"润博特"）51%的股权。具体内容详见 公司于 2023 年 7 月 21 日在上海证券交易所网站（www.sse.com.cn）披露的《青 岛蔚蓝生物股份有限公司关于收购青岛润博特生物科技有限公司 51%股权的公 告》（公告编号：2023-051）。 二、本次交易进展情况 公司于 2023 年 8 月 16 日收到润博特的通知，润博特已办理完成本次收购相 关的工商变更手续，并 ...

Financial Performance - In 2022, the company's operating revenue was CNY 1,163,162,781.39, representing a 1.07% increase compared to CNY 1,150,823,565.24 in 2021[24]. - The net profit attributable to shareholders of the listed company decreased by 47.32% to CNY 69,842,007.67 from CNY 132,573,196.74 in the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 39,713,591.08, down 57.86% from CNY 94,250,882.18 in 2021[24]. - The net cash flow from operating activities increased by 6.47% to CNY 95,306,379.54 compared to CNY 89,513,699.66 in 2021[24]. - The total assets of the company at the end of 2022 were CNY 2,578,847,636.98, a 16.07% increase from CNY 2,221,761,016.76 in 2021[24]. - The net assets attributable to shareholders of the listed company increased by 2.50% to CNY 1,644,694,382.39 from CNY 1,604,515,615.36 in the previous year[24]. - Basic earnings per share decreased by 48.15% to CNY 0.28 from CNY 0.54 in 2021[25]. - The diluted earnings per share also fell by 50.00% to CNY 0.27 compared to CNY 0.54 in the previous year[25]. - The weighted average return on net assets decreased by 5.12 percentage points to 4.30% from 9.42% in 2021[25]. - Operating costs rose to CNY 660,311,201.51, reflecting a 6.76% increase year-over-year[68]. - The overall gross margin for the company was 43.21%, which decreased by 2.61% compared to the previous year[100]. Research and Development - The company invested RMB 102.40 million in R&D, accounting for 8.80% of its operating revenue, which is relatively high in the industry[31]. - The company’s R&D expenses were CNY 102,396,593.49, a 1.45% increase from the previous year[68]. - The company has established a Nutrition and Health Technology Center, developing 16 proprietary probiotic strains and filing 57 invention patents related to probiotics[50]. - The company added 51 domestic authorized invention patents and 1 U.S. patent in 2022, bringing the total to 335 domestic authorized invention patents, 8 U.S. patents, and 2 European patents by the end of the reporting period[60]. - The company has established a national engineering technology research center for animal health products, enhancing its R&D capabilities[66]. - The company has a stable team of 278 R&D personnel, which increased by 5.3% year-on-year, including 29 PhDs and various recognized talents[64]. - The company has established multiple new technology platforms for vaccine development, including cell suspension culture and bacterial fermentation technology[101]. - The company is in the laboratory research phase for several vaccine development projects, indicating ongoing innovation efforts[114]. Market Expansion and Strategic Initiatives - The company is expanding its production capacity with the launch of the animal health industry park and the completion of the plant-based micro-ecological preparation project[32]. - A joint venture with ADM has been established to produce and sell probiotic products, targeting the global market[36]. - The company is positioned to capitalize on the growing market for functional probiotics, which are increasingly recognized for their health benefits[43]. - The company is actively addressing the challenges in the animal health industry, which faces issues such as overcapacity and product homogenization, through strategic mergers and acquisitions[45]. - The company is expanding its market presence in various sectors, including industrial, food, energy, and biocatalysis, while breaking international monopolies in some areas[61]. - The company is focusing on expanding its market presence in the enzyme and probiotic sectors, which are currently dominated by foreign brands, indicating significant potential for domestic growth[131]. - The company plans to enhance its market presence through strategic partnerships and potential acquisitions in the veterinary pharmaceutical sector[95]. Environmental and Sustainability Efforts - The company aims to achieve energy savings and emissions reductions of 30%-50% compared to traditional petrochemical routes, with future potential reaching 50%-70%[199]. - The company has invested approximately 4.37 million yuan in environmental protection during the reporting period[191]. - The enzyme products sold by the company reduced carbon dioxide emissions by approximately 2,089,405 tons in 2022[196]. - The company's phytase products reduced the use of dicalcium phosphate by approximately 67,140 tons, leading to a reduction of 107,400 tons of phosphorus emissions[192]. - The company has a commitment to sustainable practices, including the use of clean energy and new technologies to improve production efficiency and quality[196]. - The company adheres to environmental regulations and has not faced any administrative penalties related to environmental issues during the reporting period[191]. Governance and Management - The company maintains strict independence from its controlling shareholder, ensuring a robust governance structure and compliance with legal regulations[151]. - The total pre-tax remuneration for the board members amounted to 384.26 million CNY for the reporting period[156]. - The company has a strong leadership team with extensive experience in the agricultural and biotechnology sectors, as evidenced by the backgrounds of its board members[159]. - The company is committed to transparency and governance, as indicated by the detailed reporting of board member remuneration and shareholding changes[156]. - The company has established specialized committees under the board, including the Audit Committee and the Compensation and Assessment Committee[167]. - The company has implemented a risk prevention-oriented management approach to enhance the effectiveness of internal control systems and improve operational efficiency[188]. Product Development and Innovation - The company is focusing on the development of new vaccines for respiratory diseases in poultry, including a new live vaccine for Newcastle disease and infectious bronchitis[97]. - The company has developed a series of functional microbial agents for animal microecology, focusing on improving feed efficiency and providing solutions for green farming[49]. - The company has achieved breakthroughs in core technologies, including protein engineering and fermentation processes, positioning itself with a high level of R&D capability in the enzyme preparation industry[46]. - The company is actively involved in environmental microbiology technology, which is gaining traction due to its low energy consumption and effectiveness in pollution control[134]. - The company is developing functional feed enzymes to reduce costs in the livestock industry, including mycotoxin-degrading enzymes and new glucose oxidases[139]. Financial Management and Profit Distribution - The company plans to distribute cash dividends of 1.60 yuan per 10 shares, totaling approximately 40.33 million yuan (including tax) based on the total share capital of 252,084,840 shares[179]. - The company maintains a profit distribution policy that prioritizes cash dividends, aiming for at least 15% of the distributable profit to be allocated as cash dividends annually[175]. - The total cash dividend amount (including tax) is CNY 25,262,166.60, which represents 36.17% of the net profit attributable to ordinary shareholders in the consolidated financial statements[182]. - The company has not proposed a cash profit distribution plan despite having a positive profit available for distribution to shareholders[181].

Financial Performance - The company's operating revenue for Q1 2023 was ¥232,557,094.68, representing a decrease of 9.14% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2023 was ¥10,562,755.37, down 41.59% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,780,045.44, a decline of 60.66% compared to the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.04, reflecting a decrease of 42.86% year-on-year[5] - Total operating revenue for Q1 2023 was ¥232,557,094.68, a decrease of 9.1% compared to ¥255,961,097.43 in Q1 2022[15] - Net profit for Q1 2023 was ¥12,552,054.99, a decline of 36.8% from ¥19,848,538.25 in Q1 2022[16] - Total comprehensive income for Q1 2023 was CNY 12,479,517.70, a decrease of 36.9% from CNY 19,790,305.06 in Q1 2022[17] - Basic and diluted earnings per share for Q1 2023 were CNY 0.04, down from CNY 0.07 in Q1 2022[17] Assets and Liabilities - The total assets at the end of Q1 2023 amounted to ¥2,629,967,029.91, an increase of 1.98% from the end of the previous year[6] - The company's total assets increased to ¥2,629,967,029.91 in Q1 2023, up from ¥2,578,847,636.98 in Q1 2022, reflecting a growth of 2.0%[13] - Total liabilities rose to ¥884,744,898.05 in Q1 2023, compared to ¥844,934,231.18 in Q1 2022, marking an increase of 4.7%[12] - The equity attributable to shareholders at the end of Q1 2023 was ¥1,660,757,522.07, up 0.98% from the end of the previous year[6] - The total equity attributable to shareholders increased to ¥1,660,757,522.07 in Q1 2023, compared to ¥1,644,694,382.39 in Q1 2022[13] Cash Flow - The net cash flow from operating activities for Q1 2023 was ¥13,421,624.00, not applicable for year-on-year comparison[5] - Net cash flow from operating activities was CNY 13,421,624.00, compared to a negative cash flow of CNY -11,679,628.80 in the same period last year[18] - Net cash flow from investing activities was CNY -107,823,654.78, an improvement from CNY -194,348,403.12 in Q1 2022[19] - Cash inflow from financing activities was CNY 98,389,603.20, an increase from CNY 90,000,000.00 in Q1 2022[19] - Cash outflow for repayment of debts was CNY 20,200,000.00, compared to CNY 5,000,000.00 in Q1 2022[19] - The company reported a decrease in cash flow from operating activities related to other business activities, totaling CNY 9,119,903.24, down from CNY 19,805,193.77 in Q1 2022[18] Expenses - Total operating costs for Q1 2023 were ¥228,356,493.21, down 6.0% from ¥242,656,388.86 in Q1 2022[15] - Research and development expenses for Q1 2023 were ¥22,660,128.74, a decrease of 4.6% from ¥23,745,421.82 in Q1 2022[15] - The company’s financial expenses rose to ¥2,799,419.24 in Q1 2023, up from ¥716,697.27 in Q1 2022, indicating a significant increase in interest expenses[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,314[8] - The company reported non-recurring gains of ¥6,782,709.93 for the period, after accounting for tax effects and minority interests[7] - The company did not report any net profit from subsidiaries prior to consolidation in Q1 2023, consistent with Q1 2022[17] Cash and Cash Equivalents - The company's cash and cash equivalents increased to ¥975,341,333.35 in Q1 2023, slightly up from ¥969,399,325.09 in Q1 2022[12] - Cash and cash equivalents at the end of the period were CNY 181,670,560.69, slightly down from CNY 184,046,470.97 at the end of Q1 2022[19] - Revenue from sales of goods and services received cash of CNY 293,060,884.07, an increase of 9.9% from CNY 266,566,667.91 in Q1 2022[18] - The company reported an investment income of ¥4,739,753.75 in Q1 2023, significantly higher than ¥555,766.54 in Q1 2022[16]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2023-034 青岛蔚蓝生物股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 11 日(星期四) 上午 09:00-10:00 会 议 召开地点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 4 月 27 日(星期四)至 5 月 10 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过 公司邮箱 vland@vlandgroup.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 青岛蔚蓝生物股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日发 布公司 2022 年度报告和公司 2023 年第一季度报告，为便于广大投资者更全面深 入地了解公司 ...

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥532.60 million, a decrease of 3.01% compared to ¥549.10 million in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2022 was approximately ¥37.41 million, down 39.02% from ¥61.34 million in the previous year[18]. - The basic earnings per share decreased by 42.31% to ¥0.15 from ¥0.26 in the same period last year[18]. - The net cash flow from operating activities was approximately ¥15.76 million, a decrease of 2.74% compared to ¥16.20 million in the previous year[18]. - The total assets at the end of the reporting period increased by 6.74% to approximately ¥2.37 billion from ¥2.22 billion at the end of the previous year[18]. - The net assets attributable to shareholders increased by 0.32% to approximately ¥1.61 billion from ¥1.60 billion at the end of the previous year[18]. - The company reported a decrease of 50.00% in the basic earnings per share after deducting non-recurring gains and losses, from ¥0.20 to ¥0.10[18]. - The weighted average return on net assets decreased by 2.70 percentage points to 2.33% from 5.03% in the previous year[18]. Research and Development - The company invested CNY 49.99 million in R&D during the first half of 2022, accounting for 9.39% of its revenue, indicating a strong commitment to innovation[37]. - The company has developed 30 proprietary probiotic strains aimed at various health benefits, with 47 invention patents and 13 utility model patents applied for, enhancing its product portfolio in the health sector[35]. - The company has established 8 technology centers and 2 laboratories, employing 263 dedicated R&D personnel to drive sustainable development through continuous investment in new product development[25]. - The company is committed to developing new products and technologies to expand its market presence and improve product value[21]. Product Offerings and Market Focus - The company focuses on the research, production, and sales of enzyme preparations, micro-ecological preparations, and animal health products, aiming to provide core technology support for biomanufacturing and clean energy solutions for traditional industries[21]. - Key enzyme products include feed enzymes, industrial enzymes, food enzymes, and biocatalysts, which are designed to enhance feed utilization and reduce environmental pollution[22]. - The company’s micro-ecological preparations are applied across various sectors, including feed, agriculture, food, health, and pharmaceuticals, to promote gut health and enhance immune function in animals[23]. - The company aims to leverage big data systems for precise customization of enzyme combinations to maximize feed efficiency[22]. - The company is focused on expanding its product applications in various industries, including agriculture, food safety, and environmental protection[21]. Environmental Impact and Sustainability - The company sold enzyme products that cumulatively reduced carbon dioxide emissions by approximately 898,200 tons[73]. - The company’s phytase products reduced the use of dicalcium phosphate by approximately 368,800 tons and decreased phosphorus emissions into water and soil by 59,000 tons[73]. - The company actively promotes energy-saving measures, resulting in reduced consumption of raw materials, water, and electricity, thereby lowering pollutant emissions[76]. - The company has implemented new technologies and processes to improve production efficiency and quality, which has led to reduced energy consumption and carbon emissions[77]. Market Risks and Challenges - The company faces market competition risks in the enzyme preparation, micro-ecology, and animal protection industries, which could impact future performance if not addressed[62]. - Risks related to livestock epidemics and natural disasters could lead to significant economic losses and reduced demand for animal feed and related products[62]. - The company is exposed to raw material price fluctuations, which can significantly affect production costs and profitability[62]. - Exchange rate fluctuations pose a risk for the company, particularly as its export products are primarily settled in USD[63]. Corporate Governance and Compliance - The company has committed to not engaging in any competitive business activities with its controlled entities, ensuring no conflicts arise with its operations[80]. - The controlling shareholder has agreed to a lock-up period of 36 months from the date of the company's stock listing, during which no shares will be transferred or managed by others[81]. - The company will limit any share transfers to a maximum of 25% of its total holdings per year after the lock-up period ends[81]. - The company has established a clear framework for compliance with relevant laws and regulations regarding share transfers and management[81]. Financial Health and Capital Structure - The total number of ordinary shareholders as of the end of the reporting period is 11,258[93]. - The largest shareholder, Qingdao Kangdian Industrial Co., Ltd., holds 112,407,400 shares, accounting for 44.59% of total shares[95]. - The total number of restricted shares at the end of the reporting period is 35,551,040 shares[93]. - The total liabilities increased to CNY 648,386,410.47 from CNY 536,176,245.13, marking a rise of about 20.91%[107]. - The company's equity attributable to shareholders was CNY 1,609,720,351.00, slightly up from CNY 1,604,515,615.36, a growth of about 0.13%[107]. Future Outlook and Strategic Initiatives - The company provided a positive outlook for the second half of 2022, projecting a revenue growth of 20% to 30%[82]. - New product launches are expected to contribute an additional 200 million in revenue by the end of the year[83]. - Market expansion plans include entering three new international markets by Q4 2022, aiming for a 10% market share in each[83]. - The company is considering strategic acquisitions to bolster its market position, with a target of acquiring two companies by the end of the fiscal year[82].

Financial Performance - The company's operating revenue for 2021 was RMB 1,150,823,565.24, representing a year-on-year increase of 19.85% compared to RMB 960,249,354.36 in 2020[20] - The net profit attributable to shareholders of the listed company for 2021 was RMB 132,573,196.74, an increase of 21.65% from RMB 108,976,210.90 in 2020[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 94,250,882.18, reflecting a 9.70% increase from RMB 85,918,294.98 in 2020[20] - The net cash flow from operating activities decreased by 48.26% to RMB 89,513,699.66 from RMB 172,997,190.71 in 2020[20] - The total assets at the end of 2021 were RMB 2,221,761,016.76, a 53.07% increase from RMB 1,451,467,768.17 at the end of 2020[20] - The net assets attributable to shareholders of the listed company increased by 55.16% to RMB 1,604,515,615.36 from RMB 1,034,123,429.61 at the end of 2020[20] - The basic earnings per share for 2021 were RMB 0.54, up 12.50% from RMB 0.48 in 2020[21] - The diluted earnings per share for 2021 were also RMB 0.54, reflecting the same increase of 12.50% from RMB 0.48 in 2020[21] - The weighted average return on equity for 2021 was 9.42%, a decrease of 1.50 percentage points from 10.92% in 2020[21] Research and Development - The company invested RMB 100.94 million in R&D in 2021, accounting for 8.77% of its operating revenue, which is considered high in the industry[28] - The company has a strong R&D team with a balanced academic background, focusing on multi-disciplinary integration to enhance innovation capabilities in the field of probiotics and animal health[41] - The company has applied for 38 invention patents and 12 utility model patents related to probiotics, with 11 patents currently authorized[41] - The company has established 8 technology centers and 2 laboratories, focusing on market-oriented R&D and product innovation[49] - The total R&D investment for the company was RMB 195.02 million, which is competitive within the industry[104] Market Expansion and Strategy - The company plans to expand its human probiotics project, targeting a market that reached nearly RMB 85 billion in 2020[31] - The company is enhancing its service levels and efficiency to support food safety and expand into new markets such as human probiotics[28] - The company is actively exploring and expanding its global layout, particularly in regions such as Russia, Southeast Asia, and Africa, in response to international market dynamics[127] - The company aims to enhance its market network for swine vaccines and provide comprehensive disease prevention solutions for livestock farmers[135] - The company is focusing on the application of microbial technology in the environmental sector, with products already used in various pollution treatment areas, although current revenue from this segment is relatively small[132] Product Development and Innovation - The company has developed 16 proprietary probiotic strains with functions including alleviating gastrointestinal discomfort, improving skin condition, delaying aging, enhancing bone health, boosting immune function, preventing upper respiratory infections, and exhibiting antibacterial and anti-inflammatory properties[41] - The company has launched functional microbial agents for both animal and plant applications, contributing to green farming and addressing environmental concerns[40] - The company has developed and obtained clinical trial approval for several new vaccines, indicating a strong focus on innovation[102] - The company introduced new veterinary products aimed at treating various infections in livestock, including antibiotics and vaccines[93] - The company is the first in China to develop a new veterinary drug for traditional Chinese medicine and a new chemical veterinary drug for pets, indicating a strong innovation capability[97] Environmental and Social Responsibility - The company has been compliant with environmental regulations and has not faced any administrative penalties related to environmental issues during the reporting period[180] - In 2021, the company’s enzyme products helped reduce carbon emissions by approximately 2.0728 million tons[181] - The application of phytase products led to a reduction of about 668,200 tons of dicalcium phosphate usage, resulting in a decrease of 106,900 tons of phosphorus discharge into the environment[181] - The company actively promotes low-carbon initiatives among employees, including energy-saving practices and public transportation usage[184] - The company has successfully conducted 70 training sessions under the "Grow Together with You" initiative, benefiting nearly 3,200 partners and employees by 2021[188] Corporate Governance - The company maintained strict compliance with information disclosure regulations, ensuring timely and accurate reporting of relevant information[141] - The board of directors and supervisory board members actively participated in meetings, fulfilling their responsibilities diligently[141] - The company has not experienced any incidents of information leakage during the preparation of regular reports and significant events[141] - The company’s governance structure is aligned with legal and regulatory requirements, ensuring transparency and accountability[141] - The company has implemented measures to ensure the independence of its assets, personnel, and operations, with no reported issues of related party transactions affecting independence[141] Financial Management and Profit Distribution - The company implements a stable profit distribution policy, ensuring that cash dividends distributed each year are no less than 15% of the distributable profits for that year[166] - The company distributed a cash dividend of 2.00 yuan per 10 shares, totaling 36,012,120 yuan (including tax) based on a total share capital of 180,060,600 shares[169] - The profit distribution policy is subject to review and approval by the board of directors and the shareholders' meeting[169] - The company reported a positive net profit available for distribution to shareholders during the reporting period, but did not propose a cash profit distribution plan[173] - The company emphasizes the importance of independent directors in the decision-making process for profit distribution[172]

□是 √否 一、 主要财务数据 2022 年第一季度报告 证券代码：603739 证券简称：蔚蓝生物 青岛蔚蓝生物股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 (一)主要会计数据和财务指标 单位：元币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期增 | | | --- | --- | --- | --- | | | | 减变动幅度(%) | | | 营业收入 | 255,961,097.43 | | -3.83 | | 归属于上市公司股东的净利润 | 18,083,899.30 | | -37.68 | | 归属于上市公司股东的扣除非经常性损益的 | 9,608,619 ...